---
title: Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout
nct_id: NCT06887452
overall_status: NOT_YET_RECRUITING
phase: NA
sponsor: VA Office of Research and Development
study_type: INTERVENTIONAL
primary_condition: Gout
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06887452.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06887452"
ct_last_update_post_date: 2026-02-19
last_seen_at: "2026-05-12T06:42:43.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout

**Official Title:** Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients in Gout (Pharm-UP) Study

**NCT ID:** [NCT06887452](https://clinicaltrials.gov/study/NCT06887452)

## Key Facts

- **Status:** NOT_YET_RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 310
- **Lead Sponsor:** VA Office of Research and Development
- **Conditions:** Gout, Gouty Arthritis
- **Start Date:** 2026-10-01
- **Completion Date:** 2031-03-30
- **CT.gov Last Update:** 2026-02-19

## Brief Summary

This study will compare two different approaches to manage medications that lower uric acid levels. This study will be conducted at five VA medical centers across the United States and will take 4-5 years to complete. Individual participation will last up to two years.

## Detailed Description

This project will quantify and compare the effects of a pharmacist-led telehealth-delivered intervention versus usual care on arthritis flare burden and serum urate goal achievement in 310 U.S. Veterans with gout enrolled from five VA medical centers. The project will quantify the effects of the intervention on patient-reported outcomes (improvements in health-related quality of life, pain interference, and participant global assessment).

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* US Veterans over the age of 18 years with physician-diagnosed
* Documented hyperuricemia (SU \>6.8 mg/dL)
* Satisfy ACR/EULAR gout classification criteria
* Report 1 or more flares in the prior 6 months
* Receipt of a new ULT prescription (allopurinol or febuxostat) initiated by a primary care provider or longer term ULT but otherwise satisfy the flare/SU criteria

Exclusion Criteria:

* Any patient intolerant or unable to take ULTs (allopurinol or febuxostat)
* Patients with a rheumatology encounter within the prior 3 months
```

## Arms

- **Pharmacist-Led** (EXPERIMENTAL) — Veterans will participate in regular telehealth visits with study pharmacists. Serum urate lab tests will be ordered during dose escalation phase of gout treatment.
- **Usual care** (NO_INTERVENTION) — Veterans will receive standard care from their primary care provider for the management of their gout.

## Interventions

- **Pharmacist-Led** (OTHER) — Pharmacist will conduct regular telehealth visits with Veterans during dose escalation phase of gout treatment

## Primary Outcomes

- **flare occurrence** _(time frame: during year two)_ — The occurrence of two or more flares during year 2.
- **serum urate at goal** _(time frame: at end of year one)_ — Achievement of serum urate \<6 mg/dL at end of year one.

## Secondary Outcomes

- **Veterans RAND 12 (VR-12)** _(time frame: Baseline visit, Months 6, 12, 18, and 24)_
- **Patient Reported Outcomes Measurement Information System (PROMIS)** _(time frame: Baseline visit, Months 6, 12, 18, and 24)_
- **Gout-related patient global assessment** _(time frame: Baseline visit, Months 6, 12, 18, and 24)_

## Locations (5)

- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha, Nebraska, United States
- VA Portland Health Care System, Portland, OR, Portland, Oregon, United States
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States
- VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.omaha va nebraska-western iowa health care system, omaha, ne|omaha|nebraska|united states` — added _(2026-05-12)_
- `locations.va portland health care system, portland, or|portland|oregon|united states` — added _(2026-05-12)_
- `locations.corporal michael j. crescenz va medical center, philadelphia, pa|philadelphia|pennsylvania|united states` — added _(2026-05-12)_
- `locations.va salt lake city health care system, salt lake city, ut|salt lake city|utah|united states` — added _(2026-05-12)_
- `locations.va puget sound health care system seattle division, seattle, wa|seattle|washington|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06887452.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06887452*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*